Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.30 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pr-104 SCHEMBL31060232 | 0.85 | KMT2A (0.36) | POLBHPGDMEN1MAPK1KMT2A | |
| Pr-104 SCHEMBL367963 | 0.85 | KMT2A (0.36) | POLBHPGDMEN1MAPK1KMT2A | |
| SCHEMBL3585528 | 0.85 | POLB (0.32) | POLBHPGDALDH1A1PRMT5WDR77 | |
| SCHEMBL2966429 | 0.82 | HPGD (0.37) | POLBHPGDMEN1MAPK1KMT2A | |
| SCHEMBL2962640 | 0.81 | POLB (0.36) | POLBHPGDMEN1MAPK1KMT2A | |
| SCHEMBL15573005 | 0.80 | NPC1 (0.38) | POLBHPGDMEN1KMT2AALDH1A1 | |
| SCHEMBL2974746 | 0.80 | POLB (0.36) | POLBHPGDMEN1MAPK1KMT2A | |
| SCHEMBL3424835 | 0.80 | POLB (0.34) | POLBHPGDALDH1A1 | |
| SCHEMBL3584726 | 0.80 | ALDH1A1 (0.35) | POLBKMT2AALDH1A1PRMT5WDR77 | |
| SCHEMBL13338201 | 0.77 | TDP1 (0.38) | POLBHPGDMEN1MAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121091-A1 | Processes of preparing asymmetric dinitrobenzamide mustard compounds, intermediate compounds useful therein and products obtained therefrom | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121091-A1 | Processes of preparing asymmetric dinitrobenzamide mustard compounds, intermediate compounds useful therein and products obtained therefrom | HRH2, HRH4, H1-2 | POLB 2454/4885HPGD 1510/4885MEN1 2521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.